Pharma News: Vivus, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)’s Announcement & MannKind Corporation (MNKD)’s New Options

Page 1 of 2

Editor's Note: Related tickers: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD), J.C. Penney Company, Inc. (NYSE:JCP)

3 Pharmaceutical Stocks to Sell Now (InvestorPlace) This week, the ratings of three Pharmaceutical stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”). This week, VIVUS, Inc. (NASDAQ:VVUS) falls to a D (“sell”), worse than last week’s grade of C (“hold”). VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. VVUS also rates an F in Portfolio Grader’s specific subcategory of Equity. The stock price has dropped 17.4% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time.

VIVUS, Inc. (NASDAQ:VVUS)

Eye Catching Stocks for Friday's Trading Session: Arena Pharmaceuticals Inc (ARNA), J.C. Penney Company Inc (JCP) (SBWire) Pennystocksupdate.biz issues special report on - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), J.C. Penney Company, Inc. (NYSE:JCP) Arena Pharmaceuticals Inc (NASDAQ: ARNA) may have triggered an individual to create heart disease in an early-stage medical query, the company refers to, one day after introducing there had not been any serious adverse reactions during the research. Arena Pharmaceuticals, Inc. (ARNA) after opening at $6.55 hit a high price of $6.58 and then closed at $6.35 by declining -5.08% and on last session volume of 8.68 million shares was surprisingly lower than its average volume of 4.24 million shares.

MannKind Corp. VP Unloads $110,999.12 in Stock (MNKD) (WatchlistNews) MannKind Corporation (NASDAQ:MNKD) VP David Thomson sold 19,204 shares of MannKind Corp. stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $5.78, for a total transaction of $110,999.12. Following the sale, the vice president now directly owns 40,082 shares in the company. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. A number of analysts have recently weighed in on MNKD shares. Analysts at MLV Capital raised their price target on shares of MannKind Corporation (NASDAQ:MNKD).

Commit To Purchase Vivus At $8, Earn 17.1% (Forbes) Investors considering a purchase of VIVUS, Inc. (NASDAQ:VVUS) shares, but cautious about paying the going market price of $12.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2015 put at the $8 strike, which has a bid at the time of this writing of $1.37. Collecting that bid as the premium represents a 17.1% return against the $8 commitment, or a 12.3% annualized rate of return (at Stock Options Channel we call this the YieldBoost).

Arena Reports Closing of Phase 1b Clinical Trial for APD811; Astex Shares On Watch Following Positive Top-Line Data for SGI-0110 (HispanicBusiness) Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced the completion of a Phase 1b clinical trial for APD811, an investigational oral prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). The company plans to initiate a Phase 2 clinical trial for APD811 in the first quarter of 2014. "Arena's internal GPCR-focused efforts led to the discovery of this novel drug candidate," said William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer...

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 30 percentage points in 13 months Learn how!

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!